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Abbreviations 
 
Ɛ extinction coefficient 
λ wavelength 
ν frequency 
A anisotropy 
a.u. aberration units  
Ahx aminohexanoic acid 
Alloc alkyloxycarbonyl 
Azo azobenzene 
Boc tert-butylcarbonyl 
c concentration 
cAzo cyclic azobenzene 
calcd. calculated 
conc. concentration 
CuCN copper (I) cyanide 
DBU 1,8-diazabicyclo[5,4,0]undeca-7-ene 
DIC N, N’-diisopropylcarbodiimide 
DIPEA N, N’-diisopropylethylamine 
DMF N, N’-dimethylformamide 
DMSO dimethyl sulfoxide 
DTT dithiotheitrol 
E. coli Escherichia coli 
EtOAc ethyl acetate 
EDTA ethylenediaminetetraacetic acid 
ESI electrospray ionization 
eq. equivalents 
 
 
oF4Azo tetra-ortho-fluorazobenzene 
 
FAM fluorescein 
Fmoc fluorenylmethyloxycarbonyl chloride 
FP fluorescence polarization 
GSH glutathione 
HFIP hexafluoroisopropanol 
HMT histone methyltransferase 
HPLC high-performance liquid chromatography 
HRMS high resolution mass spectrometry 
IC50 half inhibitory concentration 
IPTG isopropyl β-D-1-thiogalactopyranoside 
irr. irradiation 
Kd dissociation constant 
Ki inhibition constant 
M molar 
mAU milli absorbance units 
MD Molecular Dynamics 
MLL1 mixed lineage leukaemia 1 
mP milli polarization value 
MPD 2-methyl-2,4-pentanediol 
Mtt 4-methyltrityl 
NMP N-methyl-2-pyrrolidon  
NMR nuclear magnetic resonance 
Ni-NTA nickel nitrilotriacetic acid 
PMSF phenylmethylsulfonyl fluoride 
PSS photostationary state 
PyBop benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
Rf retention factor 
RbBP5 retinoblasma-bindin-protein 5 
RP reversed phase 
rpm revolutions per minute 
r.t. room temperature 
SAM S-adenosylmethionine 
sec. seconds 
SPPS solid phase peptide synthesis 
t0 time zero 
tR retention time 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
TIS triisopropyl silane 
Tris tris(hydroxymethyl)aminomethane 
Trt trityl 
UV ultraviolet 
vis visible 
WDR5 WD-repeat protein-5 
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Experimental Procedures 
Materials 
All commercially reagents were purchased from the following companies and used without 
further purification: DMSO biograde, NaCl biograde, Tris, 2-mercaptoethanol, Fmoc-Cl, FeSO4 
× 7 H2O and DIPEA from Carl Roth (Germany); 6-aminohexanoic acid and KMnO4 from Alfa 
Aesar (Germany); OxymaPure from Luxembourg Bio Technologies (Israel); DIC, ammonium 
persulfate and glycerol from Acros (USA); Sieber amide resin, Mtt-Cl, 4-bromo-2,6-
difluoraniline and MBHA resin from Fluorochem (UK); glucose monohydrate from Applichem 
(Germany); CuCN and HCl from TCI (Japan); PyBop from Novabiochem (Germany); KCl 
biograde, Triton, 2-Cl-Trt resin, NaNO3, NaOH, KOH, 4,4’-ethylenedianiline, IPTG, ampicillin 
and dithiothreitol from Goldbio (USA); LB-broth, LB-agar, bromphenolblue and Tween-20 from 
Thermo Fisher (USA); ZnSO4 from Fluka (USA); acrylamide from National diagnostics (USA); 
glutathione-sepharose beads from GE-Healthcare (USA); protease inhibitor from Roche 
diagnostics (Germany), S-adenosylmethionine from Biolabs (USA); tert-butyl-2-bromoacetate, 
ethylenediamine, PMSF, kanamycin, NP-40 and MgSO4, from Sigma Aldrich/ Merck 
(Germany); Fmoc-protected amino acids, DMF peptide grade, HATU and TentaGel S RAM 
resin from Iris Biotech (Germany); MeCN HPLC grade, pyridine, H2SO4 and triethylamine from 
VWR (France). The H31-21 peptide and dimethylated H31-21 peptide were purchased from 
Anaspec (USA, ref. codes: AS-61702; AS-64356); The protein marker (ref. nr.: 1610373) and 
BSA stocks (ref. nr.: 500-0207) from Bio-Rad (USA). The plasmid preparation kit was 
purchased from Quiagen (ref. code: 27106, USA) and the corresponding mini-prep column 
from Denville Scientific (ref. nr.: CM-400-250, USA). Beads and buffers used for AlphaLISA 
Assay were purchased from Perkin Elmer (USA): 5 × buffer: AlphaLISA 5 × epigenetics buffer 
1 (AL008F1); 30 × buffer: AlphaLISA 30 × epigenetics buffer supplement (AL008L2); acceptor 
bead: AlphaLISA anti-H3K4me1-2 acceptor beads (AL116M); donor beads: AlphaScreen 
streptavidin donor beads (6760002). Water was purified with a Milli-Q Ultra Pure Water 
Purification System (TKA, Germany).  
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
NMR spectra were recorded at 300 K either on a Bruker AV III HD 300 MHz at a frequency of 
300 MHz (1H), 75 MHz (13C, 13C-APT) or on a Bruker AV III HD 500 MHz at a frequency of 500 
MHz (1H), 125 MHz (13C) or on a Bruker AV III HD 600 MHz at a frequency of 600 MHz (1H). 
The 1H, 13C and 13C-APT NMR spectra were referenced to solvent residue peaks. As internal 
standards, deuterated chloroform (CDCl3), deuterated dimethyl sulfoxide ([D6]DMSO) with 
TMS or deuterated water (D2O) were used. Solvent shifts (ppm): (CDCl3, δ) = 7.26 ppm (1H) 
and 77.16 ppm (13C), ([D6]DMSO, δ) = 2.50 ppm (1H) and 39.52 (13C), D2O = 4.79 ppm (1H).  
 
Mass Spectrometry 
High resolution electrospray ionization (ESI) mass spectra were acquired with a LTQ-FT Ultra 
mass spectrometer (Thermo Fischer Scientific). The resolution was set to 100,000. Field 
desorption (FD) time-of-Flight (FD-TOF/MS) mass spectra were acquired with an AccuTOF 
GCv 4G (JEOL) Time of Flight (TOF) mass spectrometer. FD-emitters were purchased from 
Linden ChroMasSpec GmbH (Bremen, Germany). 
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High Performance Liquid Chromatography (HPLC) 
For preparative purposes, a PLC 2020 Personal Purification System (Gilson) with a preparative 
Nucleodur C18 HTec-column (5 µm, 250 x 16 mm; Macherey & Nagel) with a flow rate of 
10 mL/min or a semipreparative C18 3001 coulumn (Phenomenex) with a flow rate of 8 mL/min 
using an isocratic regime during the first five minutes, for column equilibration, followed by the 
respectively stated linear gradient in 30 min at 25°C. The detection was carried out by 
measuring the absorption at wavelengths: 220 nm and 260 nm. Milli-Q water (A) and MeCN 
(B) were employed as eluents with an addition of 0.1% of TFA in both solvents. 
Analytical HPLC-MS were recorded on an Agilent 1200 Series HPLC-system (Agilent 
Technologies), with a column oven set to 55 °C. Detection was monitored at 220 nm. Milli-Q 
water (A) and MeCN (B) were employed as eluents with an addition of 0.05% and 0.03% of 
TFA. Different analytical columns and methods were used: 
- column 1: EC 125/2 Nucleodur 100-C18 ec column (Macherey & Nagel) using the 
stated linear gradient in 30 min with a flow rate of 0.20 mL/min 
- column 2:  Eclipse XBD-C18 column (Agilent Technologies) using the stated linear 
gradient in 30 min with a flow rate of 1.00 mL/min 
- column 3: Kinetex 5µm XB-C18 100Å LC column 150 × 4.6 mm (Phenomenex) using 
the stated linear gradient in 30 min with a flow rate of 1.00 mL/min  
 
UV-Vis Spectroscopy 
Concentration determinations and UV-vis measurements were performed on a Tecan 
(Switzerland) Spark 20M multimode microplate reader at r.t. All measurements were 
performed in a 1400 μL quartz cuvette (Hellma Analytics (104F-QS) with a pathlength of 1 cm. 
The, to be measured, compound was added to 700 uL of the respective blank measurement 
in the cuvette and absorbance spectra were recorded. To determine the concentration of the 
peptides the following extinction coefficients were used: oF4Azo-containing peptides (for trans 
isomer) Ɛ319 = 25000 L mol-1 cm-1 in MeCN,[1] cAzo-containing peptides (for cis isomer) 
Ɛ238 = 25990 L mol-1 cm-1 in MilliQ water, fluorescently tagged peptides Ɛ494 = 76900 L mol-1 
cm-1 in 0.1 M phosphate buffer, pH = 9[2]).  
 
Photoisomerization of oF4Azo and cAzo Peptides 
For isomerization an UV-Emitter 405 nm SMD Roschwege Star-UV405-03-00-00, 3 W (to 
reach the trans photostationary state) and a HighPower-LED Green 87 lm 130° 3.8 V, 1000 mA 
Roschwege (to reach the cis photostationary state) were used for irradiation at 405 and 
525 nm, respectively. For the irradiation at 525 nm an additional cut-on filter (OG515 coloured 
glass filter, 515 nm longpass, Thorlabs) was applied. Experiments were performed at r.t. 
 
Fluoresence Polarization-based Assay 
All FP-based assays were performed at r.t. in black 96-well microtiter plates (Greiner) and the 
FP was measured as milipolarization (mP) units on a Tecan (Switzerland) Spark 20M 
multimode microplate reader; settings: used filters, excitation: 485 nm; emission: 530 nm; gain: 
optimal; Z-position: calculated from control well (0% inhibition: tracer and protein in assay 
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buffer); number of flashes: 30; G-factor: 1.067. The data evaluation was done, using GraphPad 
Prism 6 software. 
 
Competitive Fluorescence Polarization-based Binding Assay 
The binding affinities of both isomers of each peptide were measured separately as reported 
by us previously.[3] The isomerization, however, was done differently as detailed above. The 
peptides were dissolved in DMSO biograde. In order to calculate the binding affinity of the 
trans isomers, the peptide solutions were irradiated at 405 nm for 10 sec. To determine the 
binding affinity of the cis isomers, the peptide solutions were irradiated at 525 nm for 2 min in 
a transparent glass vial, previously to the assay. Afterwards, the whole assay had to be done 
in darkness to prevent cis ® trans and trans ® cis relaxation. 120 µL of a preincubated 
complex solution of WDR5Δ23 and the tracer peptide in assay buffer (0.1 M phosphate buffer 
pH = 6.5, 25 mM KCl, 0.01% Triton) were added to 5 µL of dilutions of the respective peptide 
in DMSO in triplicate, reaching the final concentrations of 72 nM for WDR5Δ23 and 20 nM for 
the tracer peptide. Three control wells in triplicate were included in each plate: blank (without 
tracer and protein), 100% inhibition (tracer only) and 0% inhibition (protein and tracer). The 
plates were incubated on a shaker (Edmund Bühler TiMix Control TH15) at r.t. for 5 h and the 
mP values were recorded. GraphPad Prism 6 software was used for data evaluation. Ki values 
were calculated using the following equation described previously by Wang et al. and the 
corresponding webpage provided by them:[4] 
  𝐾# = 	 ['])*[+])*	,- 	.	[/]*	,- .0 
where [I]50 denotes the concentration of the free inhibitor at 50 % inhibition, [L]50 is the 
concentration of free labelled ligand at 50 % inhibition, [P]0 is the concentration of the free 
protein at 0 % inhibition, and Kd is the dissociation constant of the protein-ligand complex. 
 
Transformation, Expression and Purification of Proteins 
Cultivation of Pre-cultures 
Pre-cultures of the pET28 plasmids of WDR5Δ23, MLL1(3762-end), Ash2L (1-534), RbBP5 
(1-538) and the pGEX plasmid of GST-MLL1, used for inoculation of heterologous expression 
and starting material for plasmid preparation were prepared in test tubes with 5.00 mL LB 
medium with kanamycin for the pETH28 plasmids and with ampicillin for the pGEX plasmid. 
Then, either a colony from a plate or some cell material from a glycerol stock was scratched 
off with a toothpick and added to the test tube. The culture was incubated on a shaker at 37 
°C with 200 rpm for 16 h. For better oxygen transfer, test tubes were attached in an inclined 
way. Glycerol stocks were prepared by mixing 700 μL preculture with 300 μL 80% glycerol. 
They were flash frozen in liquid nitrogen and stored at -80 °C. 
 
Transformation 
Transformation was performed thawing aliquots of competent E. coli BL21 codon + cells on 
ice. To 25 μL of these cells, 1 μL of the respective plasmids were added. The mixture was 
incubated for 30 min on ice, followed by a heat shock in a 42 °C water bath for 45 sec. After 
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2 min incubation on ice, 250 μL of LB medium was added and the suspension was shaken at 
37 °C, 200 rpm for 1 h. Then, 50 μL were plated on LB-agar-kanamycin/ampicillin plates and 
incubated for 16 h at 37 °C. 
 
Plasmid Preparation 
The plasmid preparation was performed by the use of the Quiagen kit (see Materials section). 
Therefore, a 5.00 mL culture is prepared with the particular plasmid containing cells and 
incubated at 37 °C for 16 h. After harvesting the cells, the pellet is lysed with 250 μL 
resuspension buffer P1, which consists of RNAse that cleaves RNA and EDTA, which 
complexes the cations that normally stabilize the cell membrane. By adding 250 μL lysis buffer 
P2, which contains SDS and NaOH to disrupt the cell membrane and denatures dsDNA. Due 
to their supercoil structure, plasmids are, in contrast to genomic DNA, able to recover the 
denaturation. After mixing and incubation for 5 min, 350 μL neutralization buffer N3 was added. 
Such buffer containing KOAc, neutralizes the pH and leads to precipitation of chromosomal 
DNA and proteins. The precipitant is pelleted during a 10 min centrifugation (13000 rpm) step. 
The supernatant is then transferred onto a small column, washed once with 500 μL PB buffer, 
once with 750 μL PE buffer and finally eluted with 30 µL EB buffer or MilliQ water. 
Concentrations were measured photometric at 260 nm, which is the absorption maxima of 
nucleic acids.  
 
Expression and Purification of His-SUMO tagged Proteins 
The pET28a-based His-Sumo-Proteins (WDR5Δ23, MLL1 (3762-end), Ash2L (1-534), RbBP5 
(1-538)) were expressed from the pET28-MHL vector in E. coli BL21 codon+ cells. Expression 
was performed by inoculation of 800 mL LB medium into 2 L baffled flasks with 50 μg/mL 
kanamycin and 50 mL of pre-culture. For the expression of MLL1 and Ash2L, ZnSO4 in MilliQ 
water to a final concentration of 10 µM was added to ensure proper folding of the enzyme. The 
culture was incubated on a shaker (Multitron from Infors HT) at 37 °C and 200 rpm until an 
OD600 of 0.5-0.6 was reached. The temperature was then reduced to 20 °C and the expression 
was induced by adding IPTG up to a final concentration of 0.3 mM. The cells were grown for 
16 h and harvested through centrifugation (5000 rpm, 15 min, 4 °C, Sorvall RC6 Plus from 
Thermo Scientific). The cell pellet from the 800 mL expression culture was resuspended in 
40 mL lysis buffer (400 µL PMSF (stock: 100 mM), 400 µL 10% NP-40, 4 µL 2-
mercaptoethanole and one tablet of protease inhibitor (Roche diagnostics) cocktail in 40 mL 
BC500). Lysis of the cells was carried out using a sonicator Sonoplus HD 220 from Bandelin 
(3 x 40%, output: 4, with 2 min pulses and 3 min rest). After sonification, the suspension was 
pelleted by centrifugation (12000 rpm, 20 min, 4 °C). The lysate was added to Ni-NTA agarose 
(Quiagen, Germany) and incubated for 1 h at 4 °C. Cleavage of the His6-tag was achieved by 
incubation of the resin with 3.0 mL BC500 + 18.1 µL ULP-His6. Proteins used for the HMT-
Assay were used without further purification.  
WDR5Δ23 used for the FP-binding assays and for crystallization was further purified by loading 
onto a Mono S 5/50 GL column (GE Healthcare) using an ÄKTA purification system (GE 
Healthcare). The flow rate was 1 mL/min with the Mono S buffers A (25 mM Tris, pH = 8.0, 
20% glycerol) and B (25 mM Tris, pH = 8.0, 1 M NaCl, 20% glycerol) with first an isocratic flow 
of 100% A for 10 min followed by a linear gradient of 0-100% B in 20 min. WDR5Δ23 eluted 
between 35-40% of buffer B. The fractions were checked via SDS-PAGE and pooled. The 
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buffer was changed to the dialysis buffer (25 mM Tris, pH = 8.0, 150 mM NaCl) and the protein 
was concentrated to 200 µM. The concentrated protein was aliquoted, flash frozen in liquid 
nitrogen and stored at -80 °C. 
 
Expression and Purification of GST tagged Proteins 
The pGEX-based GST-proteins were expressed in E. coli BL21 codon+ cells. Expression was 
performed by inoculation of 800 mL LB medium into 2 L baffled flasks with 50 μg/mL ampicillin 
and 50 mL of pre-culture. For the expression of GST-MLL1, 10 µM ZnSO4 was added to ensure 
proper folding of the enzyme. The culture was incubated on a shaker (Multitron from Infors HT) 
at 37 °C and 200 rpm until an OD600 of 0.5-0.6 was reached. The temperature was then 
reduced to 20 °C and the expression was induced by adding IPTG up to a final concentration 
of 0.2 mM. The cells were grown for 16 h and harvested through centrifugation (5000 rpm, 
15 min, 4 °C, Sorvall RC6 Plus from Thermo Scientific). The cell pellet from the 800 mL 
expression culture was resuspended in 40 mL lysis buffer (400 µL PMSF (stock: 100 mM), 
400 µL 10% NP-40, 4 µL 2-mercaptoethanole and one tablet of protease inhibitor cocktail in 
40 mL BC350 (25 mM Tris, pH = 8.0, 350 mM NaCl, 20% glycerol)). Lysis of the cells was 
carried out using a sonicator Sonoplus HD 220 from Bandelin (3 x 40%, output: 4, with 2 min 
pulses and 3 min rest). After sonification, the suspension was pelleted by centrifugation 
(12000 rpm, 20 min, 4 °C). The lysate was added to glutathione-sepharose beads (GE 
Healthcare, USA) and incubated for 1 h at 4 °C. Cleavage of the GST-tag was achieved by 
incubation of the resin with 1.0 mL BC350 + 10 µM reduced glutathione for 1 h at 4°C. This 
step was repeated twice. Finally, the protein was dialysed with BC-350 without glycerol to wash 
out remaining glutathione.  
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Synthesis  
The names of the chemical compounds were generated with ChemDraw Professional (2017, 
Perkin Elmer). The commercial compounds do not have numbers, only the synthesized ones. 
 
Synthesis of Fmoc-protected cyclic azobenzene amino acid (Fmoc-
cAzoAA, 1) 
The retrosynthesis route of the Fmoc-cAzoAA 1 is illustrated in Scheme S1. In the Supporting 
Information only the procedures for the literature reported compounds are shown. The 
procedures for the novel compounds are detailed in the Manuscript, and the NMR spectra are 
shown here in the Supporting Information. 
 
 
Scheme S1. Retrosynthesis route of the Fmoc-protected cyclic azobenzene amino acid 1 (Fmoc-cAzoAA). 
 
4,4'-(ethane-1,2-diyl)bis(3-nitroaniline) (11) 
 
Scheme S2. Nitration of 1,2-bis(4-aminophenyl)ethane to the compound 11. 
 
Following the procedure of Sell at al.[5], the 1,2-bis(4-aminophenyl)ethane (1.00 g, 4.71 mmol, 
1.00 eq.) was dissolved in 8.50 mL H2SO4 (conc.) and was heated to 60 °C.  A solution of 
NaNO3 (881 mg, 10.4 mmol, 2.20 eq.) in 9.10 mL of H2SO4 (conc.) was added. After stirring at 
  
7 
60 °C for 4 h the solution was poured into 100 mL of ice water. The resulting green suspension 
was neutralized by the addition of an aqueous ammonia solution (25%). The orange precipitate 
was filtered off, washed with distilled water and dried in vacuo. The product 11 was obtained 
as an orange solid (1.30 g, 4.30 mmol, 91%). The characterization is in agreement with the 
literature.[5] TLC: Rf = 0.05 (CH2Cl2/MeOH 1:1 + 1% NEt3) 1H NMR (300 MHz, DMSO, δ): 7.06 
(d, 3J = 2.4 Hz, 2H, 2 × CHar), 6.99 (d, 3J = 8.3 Hz, 2H, 2 × CHar), 6.80 (d, 3J = 2.4 Hz, 1H, 
CHar), 6.77 (d, 3J = 2.4 Hz, 1H, CHar), 5.58 (s, 4H, 2 × NH2), 2.86 (s, 4H, 2 × CH2). 13C NMR 
(75 MHz, DMSO, δ): 149.4 (2 × Car), 148.1 (2 × Car), 132.3 (2 × Car), 121.4 (2 × Car), 118.8 (2 
× Car), 108.0 (2 × Car), 32.7 (2 × CH2). HRMS-ESI+ (m/z): calcd. for [M+Na]+ C14 H14 N4 O4 Na: 
325.0907; found: 325.0901. 
 
 (Z)-11,12-dihydrodibenzo[c,g][1,2]diazocine-3,8-diamine (6) 
 
Scheme S3. Cyclization to form the cAzo derivative 6. 
 
Following the procedure of Sell at al.[5], compound 11 (800 mg, 2.65 mmol, 1.00 eq.) was 
dissolved in 106 mL EtOH. NaOH (6.65 g, 166 mmol, 62.8 eq.) in 26.5 mL distilled water was 
added and the mixture was warmed up to 70 °C. Then, glucose monohydrate (5.39 g, 27.2 
mmol, 10.3 eq.) in 15 mL of distilled water was added. The solution was stirred at 70 °C for 
15 h. The reaction was quenched by addition of 250 mL distilled water. The product was 
extracted with EtOAc (6 × 100 mL), washed with brine and dried over anhydrous MgSO4. The 
crude was purified by flash column chromatography (pentane/EtOAc 1:1). The product 6 was 
obtained as a yellow solid (107.5 mg, 0.451 mmol, 17%). The characterization is in agreement 
with the literature.[5] TLC: Rf = 0.38 (pentane/EtOAc 1:1) 1H NMR (300 MHz, CDCl3, δ): 6.73 
(d, 3J = 8.1 Hz, 2H, 2 × CHar), 6.35 (d, 3J = 2.4 Hz, 1H, CHar), 6.32 (d, 3J = 2.4 Hz, 1H, CHar), 
6.14 (d, 3J = 2.4 Hz, 2H, 2 × CHar), 3.55 (s, 4H, 2 × NH2), 2.85.2.78 (m, 2H CH2), 2.62-2.55 (m, 
2H CH2). 13C NMR (75 MHz, CDCl3, δ): 156.4 (2 × Car), 144.9 (2 × Car), 130.6 (2 × CHar), 118.6 
(2 × Car), 114.2 (2 × CHar), 105.3 (2 × CHar), 31.2 (2 × CH2). HRMS-ESI+ (m/z): calcd. for 
[M+H]+ C14H14N4H: 239.1291; found: 239.1291. 
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NMRs of tert-butyl (Z)-(8-amino-11,12-dihydrodibenzo[c,g][1,2]diazocin-3-yl)glycinat (7) 
 
 
Figure S1. Top: 1H-NMR spectrum of the compound 7. Insert: zoom of signals in the aromatic region to highlight the shifts in Hz 
units for calculating J-constants. Bottom: 13C-APT-NMR spectrum of compound 7. 
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NMRs of tert-butyl (Z)-(8-Fmoc-11,12-dihydrodibenzo[c,g][1,2]diazocin-3-yl)glycinate (8)  
 
 
Figure S2. Top: 1H-NMR spectrum of the compound 8. Insert: zoom-in of signals in the aromatic and CH region to highlight the 
shifts in Hz units for calculating J-constants. Bottom: 13C-APT-NMR spectrum of compound 8. 
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NMRs of (Z)-(8-Fmoc-11,12-dihydrodibenzo-[c,g][1,2]diazocin-3-yl)glycinate (1) 
 
 
 
Figure S3. Top: 1H-NMR spectrum of the compound 1. Insert: zoom-in of signals in the aromatic and CH region to highlight the 
shifts in Hz units for calculating J-constants. Bottom: 13C-APT-NMR spectrum of compound 1. 
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Synthesis of Mtt-protected tetra-ortho-fluoroazobenze amino acid (Mtt-
oF4AzoAA, 2) 
The retrosynthesis route of Mtt-oF4AzoAA (2) is illustrated in Scheme S4. In the Supporting 
Information only the procedures for the literature reported compounds are shown. The 
procedures for the novel compounds are detailed in the Manuscript, and the NMR spectra are 
shown here in the Supporting Information. 
 
Scheme S4. Retrosynthesis route for the Mtt-protected tetra-ortho-fluoroazobenzene amino acid (2) (Mtt-oF4AzoAA). 
 
4-amino-3,5-difluorobenzonitrile (15)  
 
Scheme S5. Synthesis of oF2Azo derivative 15. 
 
Following the procedure of Bléger et al.[6], the 4-bromo-2,6-difluoroaniline (5.00 g, 24.0 mmol, 
1.00 eq.) and CuCN (6.45 g, 72.0 mmol, 3.00 eq.) were dissolved in 50.0 mL DMF and heated 
to 160 °C for 16 h. After cooling to r.t., the mixture was poured into a NH3 aqueous solution 
(12 %, 250 mL), filtered and the precipitate was washed serveral times with EtOAc. The 
organic phases were washed with the same NH3 solution, distilled water, brine and dried over 
anhydrous MgSO4. The crude was purified by flash column chromatography (CH2Cl2/n-
pentane 2:1) to yield the product 15 (2.33 g, 15.1 mmol, 63%) as a white solid. TLC: Rf  = 0.39 
(CH2Cl2/pentane 2:1). The characterization is in agreement with the literature.[6] 1H NMR 
(300 MHz, CDCl3, δ): 7.13 (dd, 3J = 6.0 Hz, 4J = 2.2 Hz, 2H, 2 × CHar), 4.29 (s, 2H, NH2). 13C 
NMR (75 MHz, CDCl3, δ): 152.3 (FCar), 149.1 (FCar), 129.7(Car), 118.0 (CN), 115.7 (CarH), 
115.4 (CarH); 98.4 (Car). HRMS-EI+ (m/z): calcd. for [M+H]+ C7H4F2N2, 154.03425; found, 
154.03252. 
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4-amino-3,5-difluorobenzoic acid (14) 
 
Scheme S6. Synthesis of oF2Azo derivative 14. 
 
Following the procedure of Bléger et al.[6], the 4-amino-3,5-difluorobenzonitrile (15, 1.99 g, 
12.9 mmol, 1.00 eq.) was suspended in 1 M NaOH (80.0 mL) and stirred at 110 °C for 4 h. The 
reaction mixture was cooled to r.t. and afterwards acidified with 1 M HCl (10.0 mL). The 
resulting precipitate was filtered, washed with distilled water and dried to yield the desired 
product 14 (2.23 g, 12.9 mmol, 99%) as a white solid. The characterization is in agreement 
with the literature.[6] 1H NMR (300 MHz, DMSO-d6, δ): 12.68 (s, 1H, COOH), 7.40 (dd, 3JHH 7.2, 
4JHH 2.5, 2H, 2 × CHar), 6.05 (s, 2H, NH2). 13C NMR (75 MHz, DMSO-d6, δ): 166.0 (COOH), 
151.3 (FCar), 148.2 (FCar), 130.6 (Car), 115.6 (Car.), 112.3 (CarH), 112.1 (CarH). HRMS-ESI- 
(m/z): calcd. for [M-H]- C7H4F2N1O2, 172.0216; found, 172.0217. 
 
ethyl 4-amino-3,5-difluorobenzoate (13)  
 
Scheme S7. Synthesis of oF2Azo derivative 13. 
 
Following the procedure of Bléger et al.,[6] the 4-amino-3,5-difluorobenzoic acid (14, 1.90 g, 
11.0 mmol, 1.00 eq.) was dissolved in EtOH (40.0 mL) and conc. H2SO4 (6.00 mL) and 
refluxed for 6 h. The solution was neutralized with saturated NaHCO3, extracted with CH2Cl2, 
dried over anhydrous MgSO4, filtered and the solvent was removed under reduced pressure 
to yield the desired product (13, 2.07 g, 10.3 mmol, 94%) as a pale brown solid. The 
characterization is in agreement with the literature.[6] 1H NMR (300 MHz, CDCl3, δ): 7.53 (dd, 
3J = 7.2 Hz, 4J = 2.1 Hz, 2H, 2 × CHar), 4.33 (q, 3J = 7.1 Hz, 2H, OCH2), 3.86 (s, 2 H, NH2), 1.37 
(t, 3J = 7.1, 3H, CH3). 13C NMR (75 MHz, CDCl3, δ): 165.3 (CO), 152.4 (FCar), 149.3 (FCar), 
128.9 (Car.), 118.8 (Car.), 112.8 (CarH), 112.6 (CarH), 61.2 (CH2), 14.5 (CH3). HRMS-ESI+ (m/z): 
calcd. for [M+H]+ C9H9F2N1O2H, 202.0674; found, 202.0675. 
 
 
 
 
 
 
 
  
13 
Diethyl 4,4'-(diazene-1,2-diyl)-bis(3,5-difluorobenzoate) (12) 
 
Scheme S8. Synthesis of the oF4Azo derivative 12. 
 
Following the procedure of Bléger et al.[6], the ethyl-4-amino-3,5-difluorobenzoate (13, 2.43 g, 
12.1 mmol, 1.00 eq.) was dissolved in CH2Cl2 (300 mL) and KMnO4 (20.0 g, 127 mmol, 
10.5 eq) and FeSO4 x 7 H2O (20.0 g, 71.9 mmol, 5.94 eq.) were added. The reaction mixture 
was refluxed for 28 h and filtered over celite. The solvent was removed under reduced pressure 
and the crude was purified by flash column chromatography (CH2Cl2/pentane 1:1) to yield the 
desired product 12 (748 mg, 1.88 mmol, 31%) as a red solid. The characterization is in 
agreement with the literature.[6] TLC: Rf  = 0.75 (CH2Cl2); 1H NMR (300 MHz, CDCl3, δ): 7.75 
(d, 3J = 8.9 Hz, 4H, 4 × CHar), 4.43 (q, 3J = 7.1 Hz, 4H, 2 × CH2), 1.43 (t, 3J =7.1 Hz, 6H, 2 × 
CH3).13C NMR (75 MHz, CDCl3, δ): 163.8 (2 × CO), 156.9 (2 × Car), 153.4 (2 × Car), 134.0 (2 
× Car), 133.9 (2 × Car), 114.2 (2 × Car), 113.9 (2 × Car), 62.3 (2 × CH2), 14.3 (2 × CH3). HRMS-
ESI+ (m/z): calcd. for [M+H]+ C18H14F4N2O4H, 399.0962; found: 399.0963.  
 
Diethyl 4,4'-(diazene-1,2-diyl)-bis(3,5-difluorobenzoate) (9)  
 
Scheme S9. Synthesis of oF4Azo derivative 9. 
 
Following the procedure of Bléger et al.[7], the diethyl 4,4'-(diazene-1,2-diyl)-bis(3,5-
difluorobenzoate) (12, 457 mg, 1.22 mmol, 1.00 eq.) was dissolved in THF (30.0 mL) and a 
solution of KOH (242 mg, 4.31 mmol, 3.53 eq.) in distilled water (15.0 mL) was added. The 
reaction mixture was stirred for 4 h, and then acidified with 1 M HCl (5.00 mL). The formed 
precipitate was filtered, washed with distilled water and dried on the freeze drier for 10 h to 
yield the desired product 9 (417 mg, 1.22 mmol, <99%) as a red solid. The characterization is 
in agreement with the literature.[7] 1H NMR (300 MHz, DMSO-d6, δ): 13.91 (s, 2H, 2 × COOH), 
7.82 (d, 3J = 9.3 Hz, 4H, 4 × CHar). 13C NMR (75 MHz, DMSO-d6, δ): 164.5 (2 × CO), 156.0 (2 
× Car), 152.5 (2 × Car), 135.2 (2 × Car), 133.0 (2 × Car), 114.0 (2 × Car), 113.7 (2 × Car). HRMS-
ESI- (m/z): calcd. for [M-H]- C14H5F4N2O4, 341.0191; found, 341.0203. 
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NMR of 4-((4-((2-((diphenyl(p-tolyl)methyl)amino)ethyl)carbamoyl)-2,6-difluorophenyl) 
diazenyl) -3,5-difluorobenzoic acid (2) 
 
 
Figure S4. Top: 1H-NMR spectrum of the compound 2. Insert: zoom-in of signals in the aromatic region to highlight the shifts in 
Hz units for calculating J-constants. Bottom: 13C-APT-NMR spectrum of compound 2. 
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N1-(diphenyl(p-tolyl)methyl)ethane-1,2-diamine (10) 
 
Following the procedure of Chouiki et al.[8] ethylene diamine (6.20 mL, 92.2 mmol, 9.00 eq) 
was dissolved in DCM (20.0 mL) and pyridine (14.4 mL) was added portionwise. Methyltrityl 
chloride (3.00 g, 10.25 mmol, 1.00 eq) was added at 0°C. The solution was stirred 4 h at r.t., 
before it was quenched by adding MeOH (5.50 mL) and the solvent was evaporated. The crude 
was dissolved in DCM (1% NEt3)/ distilled water (1:1; 100 mL) and the product was extracted 
with DCM (2 x 50.0 mL). The combined organic layers were washed with brine, dried over 
anhydrous MgSO4 and the solvent was removed under reduced pressure. The crude was 
purified by flash column chromatography (EtOAc + 3% NEt3). The product 10 was obtained as 
a colourless oil (2.99 g, 9.45 mmol, 92%). The characterization is in agreement with the 
literature.[8] TLC: Rf = 0.2 (EtOAc + 3% Net3) 1H NMR (300 MHz, CDCl3, δ): 7.48 (dd, 3J = 5.3 
Hz, 4H, 4 × CHar), 7.35 (d, 3J = 8.2 Hz, 2H, 2 × CHar), 7.30 – 7.22 (m, 4H, 4 × CHar), 7.21 – 
7.12 (m, 2H, 2 × CHar), 7.07 (d, 3J = 8.1 Hz, 2H, 2 × CHar), 2.79 (t, 3J = 5.9 Hz, 2H, CH2), 2.30 
(s, 3H, CH3), 2.20 (t, 3J = 6.0 Hz, 2H, CH2), 1.42 (s, 2H, NH2). 13C NMR (75 MHz, CDCl3, δ): 
146.5 (2 × Car), 143.4 (Car), 135.87 (Car), 128.8 (4 × CHar), 128.7 (2 × CHar), 128.6 (4 × CHar), 
127.9 (2 × CHar), 126.3 (2 × CHar), 70.6 (CNH), 46.7 (CH2), 43.0 (CH2), 21.1 (CH3). HRMS-
ESI+ (m/z): calcd. for [M + H]+ C22H24N2H: 317.2021; found: 317.2011. 
 
Solid Phase Peptide Synthesis 
Peptides were synthesized manually in 2 mL polypropylen reactors with plunger and frit, (pore 
size 25 μm, Multi Syn Tech GmbH, Germany; for bigger scales, 15 mL reactors were used). 
TentaGel S RAM resin (0.25 mmol/g), Cl-Trt resin (1.0-1.8 mmol/g) or Sieber-amide resin (0.3-
0.6 mmol/g), where the loading of the first amino acid for both Sieber-amide and Cl-Trt resin 
was determined, were used for synthesis.  
Determination of the resin loading: The Fmoc group of a weighted amount of resin (~5.00 mg), 
previously loaded with the first amino acid was deprotected by adding twice a solution of 20% 
piperidine in DMF for 5 min (500 µL). The filtrates were collected and the absorbance was 
measured at 300 nm (Ɛ300 (Fmoc) = 7800 M-1 cm-1)[9] on a TECAN 20M Spark plate reader and 
the loading was calculated. Loading of the resins was done as follows: 
Sieber-amide resin: 2.00 eq. Fmoc-amino acid, 2.00 eq. OxymaPure (0.5 M in DMF), 2.00 eq. 
DIC were added to the resin for 45 min with a final concentration of 0.4 M of the amino acid. 
After washing, the non-reacted amino groups were capped following the general protocol of 
manual synthesis explained below  
Cl-Trt resin: 2.00 eq. Fmoc-amino acid, 8.00 eq. DIPEA in DMF were added to the resin for 
45 min with a final concentration of 0.4 M of the amino acid. The Cl-Trt resin was capped by 
washing with 3 × DMF, 3 × DCM, 3 × DMF, 3 × MeOH, 3 × DCM.   
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Manual Solid Phase Protocol for Peptide Synthesis  
The amounts of reagents of the following synthesis protocol correspond to 20-40 μmol scale. 
For higher scales, the reagents were scaled up correspondingly. For shaking an Edmund 
Bühler Swip shaker was used. 
Swelling: The appropriate amount of resin was swollen in 1.0 mL DMF for 30 min. 
Deprotection of the temporal Fmoc group: Piperidine (500 µL, 20% in DMF) was added to the 
resin and was shaken for 5 min. This step was repeated and the resin was filtered off and 
washed with DMF (5 × 1.50 mL), CH2Cl2 (5 × 1.50 mL), DMF (5 × 1.50 mL). 
Coupling of amino acids: The Fmoc-amino acid (4.00 eq.) was dissolved in OxymaPure (0.5 M 
in DMF, except for the coupling of the the azobenzene derivatives, where OxymaPure was 
dissolved in NMP, 0.5 M, 4.00 eq.), and DIC (4.00 eq.) was added. The resulting solution was 
activated for 3 min and subsequently added to the resin. This suspension was shaken for 
45 min. The resin was filtered off and washed with DMF (5 × 1.50 mL) and CH2Cl2 
(5 × 1.50 mL) and DMF (5 × 1.50 mL). Monitoring of the coupling completion was confirmed 
by the TNBS-test[10] on few resin-beads.  
Capping: A solution of lutidine/Ac2O/DMF 6:5:89 (1.0 mL) was added to the resin and was 
shaken for 5 min. The resin was filtered off and washed with DMF (5 × 1.50 mL), CH2Cl2 
(5 × 1.50 mL) and DMF (5 × 1.50 mL). 
Cleavage deprotection step: Depending on the specific peptide the cleavage cocktail differed 
in the concentration of TFA or HFIP, type of scavengers and reaction times. The used cleavage 
cocktails and reaction times are listed below.  
- Cleavage cocktail A: 95% TFA, 5% H2O (2 h) 
- Cleavage cocktail B: HFIP/CH2Cl2 1:4 (3 h) 
- Cleavage cocktail C: 1% TFA in CH2Cl2 (2 × 30 min) 
- Cleavage cocktail D: 90% TFA, 10% H2O (90 min) 
The dried resin was treated with the corresponding mixture and was shaken for the specific 
time. After the defined time, the resin was filtered off and the filtrate was added to dry ice-cold 
Et2O (1 mL of Et2O for 100 µL cleavage cocktail). After 10 min, the precipitated peptide was 
centrifuged, the supernatant was discarded and the peptide pellet was dissolved in MilliQ in 
order to be purified. 
Purification: The probes were purified as specified above. The collected fractions, containing 
the desired peptides, were lyophilized and stored at -20 °C.  
Characterization: The freeze-dried products were identified via analytical HPLC-MS on an 
Agilent 1200 Series HPLC-system (Agilent Technologies) as detailed before. Electrospray 
Ionization Mass Spectrometry (ESI-MS) was performed as detailed before. 
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Synthesis and Characterization Data of the Peptides 
Unless otherwise noted, the synthesis of the peptides was performed manually following the 
protocol described above. The purity of the peptides was calculated from the integrated peak 
areas of the HPLC chromatograms, and is given as % for each peptide. In the chromatograms, 
the different isomers of azobenzene-containing peptides are labelled with their respective 
retention times above the respective peak and assigned in the text into brackets. 
 
4: H2N-Ser-Ala-Arg-Ala-cAzo-Val-His-Leu-Arg-Lys-Ser-CONH2; For the final cleavage step, 
the resin (scale = 20 µmol, loading = 0.25 mmol/g) was treated with 2.00 mL cleavage cocktail 
A. After purification, the product 5 × TFA salt (3.8 mg, 1.83 µmol, 9%) was obtained as a yellow 
solid. tR = 23.36 min (cis). Purity ≥ 99%. Formula: C63H100N24O13. HRMS-ESI+ (m/z): [M+2H]2+ 
calcd.: 701.4026; found: 701.4028. 
 
Figure S5. HPLC chromatogram of purified peptide 4. Gradient: 5-40% B on column 1. 
 
16: Boc-Ser(tBu)-Ala-Arg(Boc)2-Ala-COOH; For the final cleavage step, the resin 
(scale = 0.35 mmol, loading = 0.832 mmol/g) was treated with 14.00 mL cleavage cocktail B. 
After purification, the product (146.5 mg, 0.193 mmol, 55%) was obtained as a white solid. 
tR = 24.09 min. Purity = 99%. Formula: C34H61N7O12. HRMS-ESI+ (m/z): [M+H]+ calcd.: 
760.4451; found: 760.4445. 
 
Figure S6. HPLC chromatogram of purified peptide 16. Gradient: 5-95% B on column 1. 
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17: H2N-oF4Azo-Val-His(Trt)-Leu-Arg(Boc)2-Lys(Boc)-Ser(tBu)-CONH2; For the final cleavage 
step, the resin (scale = 80 µmol, loading = 0.513 mmol/g) was treated with 6.00 mL cleavage 
cocktail C, 2 × for 30 min. After purification, the product 1 × TFA-salt (33.9 mg, 18.7 µmol, 
23%) was obtained as an orange solid. tR = 14.95 min (cis, product - 1Boc), 15.70 min (trans, 
product - 1Boc), 19.55 min (cis), 20.39 min (trans). Purity = 91%. Formula: C86H116F4N17O15. 
HRMS-ESI+ (m/z): [M+H]+ calcd.: 1703.8798; found: 1703.8778. 
 
Figure S7. HPLC chromatogram of purified peptide 17. Gradient: 35-95% B on column 2. 
 
Ligation of fragments 16 and 17   
 
Scheme S10. Ligation of fragments 16 and 17 to form final oF4Azo-peptide 5. 
 
5: H2N-Ser-Ala-Arg-Ala-oF4Azo-Val-His-Leu-Arg-Lys-Ser-CONH2; Ligation of the two 
fragments 16 and 17 was performed in solution. Therefore, 17 (33.9 mg, 0.0187 mmol, 
1.00 eq.) was dissolved in 187 µL DMF and DIPEA (3.30 µL, 0.0187 mmol, 1.00 eq) was 
added. Peptide 17 (42.6 mg, 0.056 mmol, 3.00 eq.) was separately, dissolved in 187 µL DMF, 
where PyBop (29.1 mg, 0.056 mmol, 3.00 eq.) and DIPEA (26.1 µL, 0.15 mmol, 8.00 eq) were 
added and the mixture was activated for 3 min before it was added to the solution of 17. The 
reaction mixture was shaken for 30 min. After purification, the side chain protecting groups 
were deprotected by treatment of the crude with 20 mL cleavage cocktail D. The product was 
precipitated in ice cold Et2O, dissolved in water and irradiated at 520 nm as explained before 
to obtain the cis isomer, which was isolated via preparative HPLC. The product 5 × TFA-salt 
(6.9 mg, 3.35 µmol, 18%) was obtained as an orange solid. tR = 21.74 min (cis), 22.25 min 
(trans). Purity = 99%. Formula: C63H98F4N24O14. HRMS-ESI+ (m/z): [M+2H]2+ calcd.: 745.3810; 
found: 745.3804. 
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Figure S8. HPLC chromatogram of purified peptide 5. Gradient: 5-40% B on column 2. 
 
 
Results and Discussion  
Screening for Suitable Fmoc-deprotection Conditions 
To test whether the oF4Azo motif could be introduced into the peptide backbone as an Fmoc-
amino acid building block, first the stability of the compound 9 against 5% piperazine in DMF 
and 2% DBU in DMF was evaluated since these conditions could be used as mild protocol for 
Fmoc-deprotection in SPPS. 
 
  
Figure S9. HPLC chromatograms of oF4Azo compound 5. Gradient 5-95% B on column 2. Left: 5% piperazine in DMF, 10 min. 
Right: 2% DBU in DMF, 10 min. Mass of degradation products indicated on top of the peak in square brackets and g/mol. 
  
As obvious from the HPLC chromatograms these conditions are not compatible with the 
stability of 9, since they lead to adduct formation as side products in the case of the piperazine 
and substitution side products in the case of DBU. 
To further evaluate this, we incorporated the Mtt-oF4AzoAA 2 to the peptide backbone of the 
VHLRKS-peptide fragment via the general SPPS method detailed before. As shown in Scheme 
S11, the Mtt-protecting group was removed on the resin via washing the resin with 1% TFA in 
DCM (10 × 1 min) followed by the washing with DCM, DMF, MeOH, DMF, DCM and DMF 
(each 3 × 1 min). Then, the resin was again washed with 20% DIPEA in DMF (5 × 3 min), 
before Fmoc-Ala-OH was coupled according to the usual SPPS protocol. 
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Scheme S11. On resin Mtt-deprotection and coupling of Fmoc-Ala-OH to the oF4Azo-peptide fragment. 
 
The HPLC chromatogram and the ESI spectrum of the cleaved compound 18 are shown in 
Figure S10 (19.12 and 19.89 min: cis and trans isomer of 18, respectively). 
  
Figure S10.. Left: HPLC chromatogram of Fmoc-protected product 18 with a mass of 1398.51 g/mol. Gradient 5-95% B, column 
2. Right: ESI spectrum of compound 18. 
 
The resin was then incubated with the respective Fmoc-deprotection conditions (see Scheme 
S12 and Table 1, Manuscript) and then washed and dried as in the general SPPS protocol. 
Next, a test cleavage with the cocktail D (90% TFA, 10% H2O, 90 min) was performed and 
HPLC chromatograms were recorded (5-95% B, column 2), which are shown in Figure S11 till 
Figure S13.  
 
Scheme S12. Reaction for the evaluation of different Fmoc-deprotection conditions on the peptide fragment 18. 
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The peaks at 19.12 and 19.89 min correspond to the Fmoc-protected peptide 18 with a mass 
of 1398.51 g/mol. The peak at 14.25 min corresponds to the desired Fmoc-deprotected 
product 19 with a mass of 1176.2 g/mol. The masses of the additional new peaks are indicated 
in square brackets in g/mol above the respective peak. 
  
Figure S11. HPLC chromatograms after Fmoc-deprotection and resin cleavage with cocktail D. Gradients 5-95% B, column 2. 
Left: Conditions A incubated for 17 h. Right: Conditions B incubated for 17 h. 
  
Figure S12. HPLC chromatograms after Fmoc-deprotection and resin cleavage with cocktail D. Gradient 5-95% B, column 2. Left: 
Conditions C incubated for 17 h. Right: Conditions D incubated for 90 min. 
  
Figure S13. HPLC chromatograms after Fmoc-deprotection and resin cleavage with cocktail D. Gradient 5-95% B, column 2. Left: 
Conditions E incubated for 3 h. Right: Conditions F incubated for 16 h. 
 
As can be seen, almost none of the above detailed conditions could prove to be efficient for 
Fmoc deprotection without the degradation of the peptide (A, B, C, D). The only exception is 
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condition E/F, with which it was possible to deprotect the Fmoc group without a notably high 
degradation of the peptide.  
 
Extinction Coefficients 
The extinction coefficient of cAzo-containing peptide 4, was measured in MilliQ water at r.t. A 
specific amount of the compound 4 (> 5.00 mg) was accurately weighted on a Mettler Toledo 
XP6 micro balance to prepare a solution of known concentration. Increasing amounts of the 
corresponding stock solution were added without exceeding 10 % of the initial volume of the 
cuvette; absorbance was measured as explained before. In all the cases the recorded 
absorbance was between 0.1 and 1 a.u. to be in concordance with Lambert-Beer law:  
A = ε ∙ c ∙ l 
where A = absorbance; ε = molar extinction coefficient; c = concentration; l = path length. 
The lineal regression of the obtained absorbance measurements versus the concentrations of 
the corresponding compound allowed us to obtain the molar extinction coefficient and 
regression value (R2). The background signal was subtracted.  
The obtained molar extinction coefficient in MilliQ water is: Ɛ494 = 25990 L mol-1 cm-1 with 
R2 = 0.995  
In the case of the other peptides the following extinction coefficients were used: oF4Azo 
containing peptides (for trans isomer) Ɛ319 = 25000 L mol-1 cm-1 in MeCN,[1] cAzo containing 
peptides (for cis isomer) Ɛ238 = 25990 L mol-1 cm-1 in MilliQ water, fluorescently tagged 
peptides Ɛ494 = 76900 L mol-1 cm-1[2] in 0.1 M phosphate buffer, pH = 9). 
 
 
Figure S14. Linear fit of the triplicate measurements to obtain the extinction coefficient of cAzo-containing peptide 4. 
 
UV-vis Characterization 
For the characterization via UV-vis measurements of the oF4Azo-containing peptide 5 and 
cAzo containing peptide 4, a Tecan (Switzerland) Spark 20M multimode microplate reader was 
used. 200 µL of a 0.262 mM solution of oF4Azo-containing peptide 5 in MilliQ water was added 
to a blank of 300 µL MilliQ water in a cuvette (final conc.: 0.105 mM). The cuvette was irradiated 
at the respective wavelengths for the indicated times, followed by measuring the absorbance 
spectra at r.t. To evaluate the required time of irradiation to reach the photostationary state 
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(PSS) of one isomer, the two isomers were irradiated for different times. The absorbance 
spectra are shown in Figure S15. 
  
Figure S15. UV-vis spectra of oF4Azo-containing peptide 5. Left: irradiation of trans isomer at 520 nm to obtain the cis isomer. 
Right: irradiation of cis isomer at 405 nm to obtain the trans isomer. 
 
For the characterization via UV-vis measurements of the cAzo-containg peptide 4, 100 µL of 
a 0.51 mM solution of cAzo-containg peptide 4 in MilliQ water was added to a blank of 300 µL 
water in a cuvette (final conc.: 0.128 mM). The procedure was the same as detailed above. 
The absorbance spectra are shown in Figure S16. 
  
Figure S16. UV-vis spectra of cAzo-containg peptide 4. Left: irradiation of trans isomer at 520 nm to obtain the cis isomer. Right: 
irradiation of cis isomer at 405 nm to obtain the trans isomer. 
 
RP-HPLC Characterization 
In the case of the oF4Azo-containing peptide 5 the trans isomer is the thermodynamically more 
stable one. Contrarily for the cAzo-containing peptide 4, the cis isomer is thermodynamically 
favoured due to the ring strain of the trans isomer. To evaluate the ratio of each isomer at their 
photostationary states, as well as examining the stability of each isomer in total darkness, we 
used RP-HPLC, if not stated differently, the column 3 and a gradient of 10-35% B for oF4Azo-
containing peptide 5 and 5-40% B for cAzo-containing peptide 4 were used.  
For the isomerization, a 120 µM solution of the corresponding peptide in MilliQ water was 
irradiated at 405 nm for 5 sec to obtain the trans isomer, and at 520 nm for 1 min to obtain the 
cis isomer for the oF4Azo-containg peptide 5. For the cAzo-containing peptide 4, at 405 nm for 
1 min to obtain the trans isomer, and at 520 nm for 10 sec. to obtain the cis isomer. The 
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photostationary states reached upon irradiation were determined by integrating the peak areas 
in the HPLC chromatograms at 275 nm (oF4Azo- containing peptide 5, isosbestic point) and at 
395 nm (cAzo-containing peptide 4); due to the low ratio of the trans isomer in its 
photostationary state, the isosbestic point is not clearly visible in these spectra. Because of 
this, the cis/trans ratio of peptide 4 was determined via HPLC at 395 nm, which is the 
wavelength where both isomers show the same height of absorbance and have, therefore, the 
same extinction coefficient). To evaluate the relaxation times, the peptide solutions were stored 
in total darkness at r.t. and HPLC chromatograms were recorded after the indicated time 
periods, shown in Figure S17 for the oF4Azo-containing peptide 5 and in Figure S18 for the 
cAzo-containing peptide 4.  
  
Figure S17. HPLC chromatograms of oF4Azo-containg peptide 5 incubated in total darkness. HPLC chromatograms were 
recorded after the indicated time. c: cis, t: trans, sp: side product. Left: after irradiation at 520 nm to reach the photostationary 
state of the cis isomer. Right: after irradiation at 405 nm to reach the photostationary state of the trans isomer. s.p.: indication of 
ratio of side products. 
  
Figure S18. HPLC chromatograms of cAzo-containg peptide 4 incubated in total darkness. HPLC chromatograms were recorded 
after the indicated time. c: cis, t: trans, sp: side product.  Left: no irradiation; photostationary state of the cis isomer. Right: after 
irradiation at 405 nm to reach the photostationary state of the trans isomer. s.p.: indication of ratio of side products. 
 
NMR Characterization 
To confirm the ratio between isomers of the oF4Azo-containing peptide 5, obtained by HPLC 
characterization, we used 1H-NMR. The NMR spectra of peptides 5 was recorded in D2O at 
300 K a Bruker AV III HD 600 MHz at a frequency of 600 MHz (1H), as detailed above. The 
peptide was dissolved in D2O to give a solution of 1.34 mM concentration. Then, the solution 
was irradiated at the corresponding wavelength as detailed above and 1H-NMRs of each 
isomer were recorded. The aromatic region of the spectra are shown in Figure S19. The 
cis/trans ratios were calculated by integrating the peak areas of these aromatic proton signals, 
(5: irr. at 405 nm: cis/trans: 8:92; at 520 nm: 84:16 by NMR) and they corroborate the HPLC 
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25 
ratios. Of note, under our conditions neither the amide protons[11–13] nor the aromatic histidine 
protons[14,15] were visible. 
  
Figure S19. Selected aromatic region of the 1H-NMR spectra (600 MHz) of a1.34 mM solution of oF4Azo-peptide (5) in D2O after 
irradiation to the trans- (top, blue) and cis (bottom, green) isomer. Aromatic protons are marked in colours on the spectra and 
molecules. 
 
Stability against Glutathione 
The stability of the peptides 5 and 4 against glutathione (GSH) was evaluated by incubating 
3.5 μL of a 250 mM stock of GSH with 80 μL of a 100 μM solution of the respective peptide in 
MilliQ water giving final concentrations of 10 mM of GSH and 96 μM of the peptides, 
respectively at r.t. After different time periods, HPLC chromatograms of these mixtures were 
recorded and are shown in Figure S20 to Figure S21 (column 3, gradient of 10-35% B for 
oF4Azo-containing peptide 5 and 5-40% B for cAzo-containing peptide 4).  
  
Figure S20. HPLC chromatograms of oF4Azo-peptide (5) incubated with 10 mM reduced glutathione at 275 nm. The solutions 
were stored in darkness and HPLC chromatograms were recorded after the indicated time. c: cis, t: trans, sp: side product.  Left: 
after irradiation at 520 nm to reach the photostationary state of the cis isomer. After 4 days incubation, the solution was irradiated 
at 405 nm to switch back to the photostationary state of the trans isomer (red). Right: after irradiation at 405 nm to reach the 
photostationary state of the trans isomer. After 4 days incubation, the solution was irradiated at 520nm to switch back to the 
photostationary state of the cis isomer (yellow). 
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Figure S21. HPLC chromatograms of cAzo-peptide (4) incubated with 10 mM reduced glutathione. The solutions were stored in 
darkness and HPLC chromatograms were recorded after the indicated time. c: cis, t: trans, sp: side product.  Left: after irradiation 
at 520 nm to reach the photostationary state of the cis isomer. After 4 days incubation, the solution was irradiated at 405 nm to 
switch back to the photostationary state of the trans isomer (red). Right: after irradiation at 405 nm to reach the photostationary 
state of the trans isomer. After 4 days incubation, the solution was again irradiated at 405 nm to switch back to the photostationary 
state of the trans isomer (red). s.p.: indication of ratio of side products. 
 
Fluorescence Polarization-based Assay 
Competitive Fluorescence Polarization-based Binding Assays 
The FP-binding experiments were performed in triplicate and three times independently. The 
results are represented in Table S1 and the FP spectra are shown in Figure 2 (Manuscript). 
 
Table S1. Mean ± SD of the IC50 and Ki values of peptides 4 and 5 of three independent measurements. 
peptide Exp. 
PSS at 
405 nm 
IC50 [µM] 
PSS at 
520 nm 
IC50 [µM] 
PSS at 
405 nm Ki 
[µM] 
PSS at 
520 nm 
Ki [µM] 
ratio 
H2N-SARAoF4AzoVHLRKS  
(5) 
1 
0.757 1.88 10.9 28.7 2.63 
 2 0.759 1.91 11.0 29.1 2.65 
 3 0.913 2.27 13.4 34.7 2.59 
 mean 0.810 ± 0.089 
2.02 ± 
0.21 
0.0118 ±  
0.0014 
0.0308 ±  
0.0033 2.61 
H2N-SARAcAzoVHLRKS  
(4) 
1 
7.07 9.58 0.110 0.150 1.36 
 2 8.53 16.1 0.133 0.252 1.89 
 3 11.4 14.0 0.178 0.220 1.24 
 mean 8.98 ± 2.18 
13.2 ± 
3.3 
0.140 ± 
0.035 
0.207 ± 
0.052 1.48 
 
To verify that the used assay conditions do not influence the cis/trans ratio, a control well with 
5 µL of the respective peptide in DMSO irradiated at 525 nm (cis), as well at 405 nm (trans), 
each diluted with 120 µL assay buffer were included in each plate. Before and after the assay, 
HPLC chromatograms of such controls were recorded at the respective isosbestic points 
(gradient: 5-40% B, column 2). We did not observe any influence on cis/trans ratio due to the 
assay conditions. The chromatograms are shown in Figure S22 to Figure S25. Cis and trans 
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27 
isomers are labelled with their respective retention times (5, cis: 20.07/19.91 min; 5, trans: 
20.40/20.49 min; 4, cis: 20.02 min; 4, trans: 20.42 min). 
  
Figure S22. HPLC chromatograms of peptide 5 (SARA-oF4Azo-VHLRKS) before the FP-based assay. Left: irradiated peptide at 
405 nm. Right: irradiated peptide at 520 nm. 
  
Figure S23. HPLC chromatograms of peptide 5 (SARA-oF4Azo-VHLRKS) after the FP-based assay. Left: irradiated peptide at 
405 nm. Right: irradiated peptide at 520 nm. 
  
Figure S24. HPLC chromatograms of peptide 4 (SARA-cAzo-VHLRKS) before the FP-based assay. Left: irradiated peptide at 
405 nm. Right: irradiated peptide at 520 nm. 
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Figure S25. HPLC chromatograms of peptide 4 (SARA-cAzo-VHLRKS) after the FP-based assay. Left: irradiated peptide at 
405 nm. Right: irradiated peptide at 520 nm. 
 
Crystallisation of WDR5Δ23-Peptide 4 Complex 
Figure S26 shows an overlay of the whole structures of the superimposed cAzo-peptide (4) 
with AMPB-peptide (3), as well as the ribbon representation of 4 showing its helical 
conformation.  Figure S27 represents the hydrogen bonds of peptide 4 to WDR5.  
 
 
 
Figure S26. Right: Superposition of the crystal structure of the WDR5Δ23/cAzo peptide 4 and WDR5Δ23/AMPB-peptide (3) 
(peptide 3: orange, peptide 4: green). Left: Ribbon representation of cAzo-peptide (4) (green) showing its helical conformation. 
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Figure S27. Hydrogen bond network of peptide 4 to WDR5Δ23 (peptide 4: green). Interacting protein residues are labelled. 
 
All the interactions between peptide 4 with WDR5Δ23 are shown in Figure S28 and are 
additionally listed in Table S2. 
 
 
 
Figure S28. Schematic representation of the key interactions between the cAzo-peptide 4 and WDR5Δ23. Left: SARA part. Right: 
cAzo-VHLRKS part. Generated with LIGPLOT.[16]  
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Table S2. Interactions between the cAzo-peptide (4) and WDR5Δ23. 
peptide Hydrogen-bond/ Van der Waals partner 
Residue Atom WDR5 residue Atom Distance (Å) 
Ser1 OG Ser91 OG 2.86 
Ser1 N Asp107 OD2 3.14 
Ala2 N Asp107 OD1 2.90 
Arg3 O water (bridge to 
Cys261, N) 
O 2.80 
Arg3 NH1 Cys261 
water (bridge to 
Ser175, O) 
O 
O 
2.92 
2.84 
Arg3 NH2 Phe133 
water (bridge to 
Ser175, O and via 
another water to 
Ser218, O) 
O 
O 
3.03 
2.98 
Ala4 O water (bridge to 
Tye260, O) 
water (bridge to 
Glu322, N) 
 2.85 
 
2.96 
cAzo  O water (bridge to 
Tyr191, OH) 
water (bridge to 
lys259, NH2) 
 2.82 
Arg9 O Water (bridge to 
Asp172, OD1) 
O 2.63 
        H-bond cut off < 3.5 Å, Van der Waals: 3.6-4.0 Å. 
 
Docking and Molecular Dynamics (MD) Studies 
The following Figures show the differences between poses obtained from molecular docking, 
molecular dynamics (MD) and the crystal structure of AMPB-peptide (3, PDB code: 5M23), 
as well as RMSD fluctuations during 20 ns of molecular dynamics, and fluctuations of residues 
from peptidomimetics during 20 ns of molecular dynamics simulations. Furthermore, the 
measured distances between leucine and tetra-ortho-fluorazobenzene, the difference in 
binding modes obtained for cis AMPB-peptide (3) and cis oF4Azo-peptide (5) and the surface 
area of protein-peptidomimetics binding. Additionally, Figures that show the different binding 
modes of the AMPB-peptide (3) and the cis/trans oF4Azo-peptide (5) obtained by MD, are 
represented, as well as the difference of computational predicted binding modes between cis 
and trans cAzo-peptide (4). 
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Figure S29. Difference between pose of trans AMPB-peptide (3) obtained by molecular docking (red sticks) and pose from PDB 
ID:5M23 (orange sticks). 
 
 
 
 
Figure S30. RMSD fluctuations during 20 ns of molecular dynamics production runs calculated for whole protein. 
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Figure S31. Fluctuations of residues from peptidomimetics expressed as root mean square fluctuations (RMSF) during 20 ns of 
molecular dynamics simulations. 
 
 
Figure S32. Comparison between binding modes of trans AMPB-peptide (3) predicted in MD simulation (red) and the described 
in the crystal structure PDB code: 5M23 (orange). 
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Figure S33. Comparison between binding modes predicted in MD simulations for trans AMPB-peptide (3) (red) and for trans 
oF4Azo-peptide (5) (dark purple). 
 
 
Figure S34. Measured distances between leucine of trans oF4Azo-peptide (5) (-VHLRKS sequence of peptides) and tetra-ortho-
fluoroazobenzene during 20 ns of simulation. Stabilization of intramolecular interaction was achieved after 7 ns.  
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Figure S35. Comparison between binding modes predicted in MD simulations for trans AMPB-peptide (3) (red) and for cis 
oF4Azo-peptide (5) (light purple). 
 
 
Figure S36. Comparison between binding modes predicted in MD simulations for trans AMPB-peptide (3) (red) and for trans 
cAzo-peptide (4) (dark green). 
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Figure S37. Comparison between binding modes of cis cAzo-peptide (4) computationally predicted (turquoise) and the described 
in the crystal structure PDB code: 6IAM (green). 
 
Table S3. Average and standard deviation for RMSD values through 20 ns of MD runs. 
ID Average Standard Deviation 
trans AMPB-peptide (3) 0.080306 0.017255 
cis AMPB-peptide (3) 0.213613 0.034478 
trans oF4Azo-peptide (5) 0.214039 0.04802 
cis oF4Azo-peptide (5) 0.224058 0.033466 
trans cAzo-peptide (4) 0.221753 0.033309 
cis cAzo-peptide (4) 0.243952 0.086662 
 
Table S4. Surface area of protein-peptidomimetics binding surface calculated by Volaera.[17] 
ID Binding surface area (Å2) 
trans AMPB-peptide (3) 2153.999 
cis AMPB-peptide (3) 1643.134 
trans oF4Azo-peptide (5) 1617.568 
cis oF4Azo-peptide (5) 1533.619 
trans cAzo-peptide (4) 1827.268 
cis cAzo-peptide (4) 1287.747 
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